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ScienceDirectA prime objective of genomic medicine is the identification of
disease-causing mutations and the mechanisms by which such
events result in disease. As most disease phenotypes arise not
from single genes and proteins but from a complex network of
molecular interactions, a priori knowledge about the molecular
network serves as a framework for biological inference and
data mining. Here we review recent developments at the
interface of biological networks and mutation analysis. We
examine how mutations may be treated as a perturbation of the
molecular interaction network and what insights may be gained
from taking this perspective. We review work that aims to
transform static networks into rich context-dependent
networks and recent attempts to integrate non-coding RNAs
into such analysis. Finally, we conclude with an overview of the
many challenges and opportunities that lie ahead.
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Introduction
Genome-wide association studies (GWAS) have ident-
ified numerous risk loci for common complex diseases,
and next-generation sequencing (NGS) based association
strategies are now emerging to characterize the contri-
bution of rare variants to human genetic disorders [1,2].
While these studies have provided useful insights into the
heritability of diseases, prediction of disease risk from
genetic information remains challenging. In addition,
Open access under CC BY-NC-SA license.www.sciencedirect.com without a basic understanding of the biological mechan-
isms by which most of the candidate loci cause disease, it
remains difficult to develop therapeutic strategies for
countering them.
The phenotypic effects of genetic alterations result from
disruptions of biological activities within cells. These activi-
ties arise from the coordinated expression and interaction of
various molecules such as proteins, nucleic acids and metab-
olites [3–7]. Networks can provide a framework for visualiz-
ing and performing inference on the set of intracellular
molecular interactions and are a promising intermediate
for studying genotype–phenotype relationships.
In the ideal case, a candidate locus can be linked to
phenotype using canonical ‘pathways’ curated from the
biomedical literature, that is, sequences of experimentally
characterized molecular interactions that give rise to a
common function. For example, Lee et al. identified can-
didate de novo somatic mutations in cases of hemimega-
lencephaly (HME) [8] and found an enrichment of
mutations in genes encoding key proteins in the canonical
PIK3CA-AKT-mTOR pathway in the affected brain tis-
sue. On the basis of structure of this well-studied pathway,
they applied an assay to detect pathway activity down-
stream of the mutation events and determined that the de
novo mutations were associated with elevated mTOR
activity. Their findings further suggest that patients with
HME may benefit from treatment with mTOR inhibitors.
In most cases, candidate genes implicated by GWAS or
NGS-based studies are not well characterized and their
products are not included in available canonical signaling
pathways; furthermore, canonical pathways are likely to
be incomplete and may even be inaccurate [7]. Systema-
tic screens of the proteome suggest that canonical path-
ways capture only a fraction of the true protein–protein
interactions that occur within the cell [9] and many such
interactions may depend on tissue and condition-specific
factors [10]. In addition, new classes of molecule such as
microRNAs and lincRNAs are increasingly implicated in
regulating the activity of protein coding genes [7,11–14].
In contrast to canonical pathways, network models are
often built from systematic experimental screens, broad
surveys of the literature or public databases of molecular
interactions. These models can easily be extended to
incorporate new molecular species or different types of
relationship between molecules and represent essential
tools for biological inference. Nonetheless, it is important
to be aware that networks are subject to various ascertain-
ment biases including those introduced by measurementCurrent Opinion in Genetics & Development 2013, 23:611–621
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A hierarchical perspective of biological interactions mediating genotype–phenotype relationships. Protein activity is determined by protein amino acid
sequence and structure. Proteins contribute to biological processes through interactions with other molecules in the cell. Biological processes arise
from coordinated groups of molecular interactions, and in turn can interact to mediate higher order cellular behaviors and responses to environmental
cues. Advances in several areas of network research are improving our understanding of how the organization of biological systems mediates
genotype–phenotype relationships. This knowledge will be essential for identifying mutations underlying disease associations and their mechanisms of
pathogenesis.technologies, selection of proteins for systematic study or
due to variation in the number of experiments or studies
performed for particular genes.
Modeling genotype–phenotype associations will
require understanding the consequences of genetic
alterations at multiple scales (Figure 1), several of
which can be modeled with networks. Genetic altera-
tions impacting the abundance or activity of individ-
ual molecules will affect the interactions in which
those molecules participate. If the affected inter-
actions are an important component in the larger
network mediating a critical biological process or
cellular behavior, a disease phenotype is more likely
to occur. Here, we review developments in modelingCurrent Opinion in Genetics & Development 2013, 23:611–621 molecular interactions within the cell, how mutations
impact molecular interactions and biological processes
in disease phenotypes, and how this knowledge can
be exploited to elucidate key genotype–phenotype
relationships.
Networks for biological inference
Networks provide a framework for deriving information
from a set of relationships among biological entities. In
models of subcellular biological processes, network nodes
are typically genes, proteins, nucleic acids or metabolites,
and edges represent physical interactions or a rich variety
of functional associations (Table 1). Hybrid networks that
are mixtures of different types of relationships are preva-
lent as well.www.sciencedirect.com
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Table 1
A summary of several common varieties of biological network and some examples.
Network type Nodes Edges Example
Protein–protein interaction (PPI) Proteins Physical interactions HPIN [26]
Structurally resolved PPI Protein Physical interactions HSIN [26], SIN [58],
Interactome3D [44], INstruct [45]
Protein–DNA interaction Transcription factors Transcription factor DNA binding [91,92]
Co-expression Proteins Common expression [93]
Genetic interaction (GI) Genes Common function [18,69]
Difference Genes Differential function [66]
Metabolic Enzymes, metabolites Biochemical reactions [94]
Non-coding RNAs miRNA, lincRNA, asRNA,
target genes
Physical interactions,
common function
[95]
Integrated Any Any HumanNet [54], BioGrid [96]
Hierarchical Any Any Nexo [90]Biological network models can be constructed from sys-
tematic genome-wide unbiased screens or focused interrog-
ation of distinct biological functions. For complex disorders
that are poorly characterized, mapping candidate genes andTable 2
Summary of recent network-based strategies for identifying biologica
into two types: Exploratory Methods evaluate biological trends relating
specific mutation, gene or biological pathway underlying a specific 
DE = differential expression, eQTL = expression quantitative trait locu
Type Goal Data 
Exploratory Network for analysis of disorders
associated with blood vessels
Protein interactions, prot
domains
Network for analysis of HIV host
cell defense evasion
mechanisms
Affinity-tagging purificatio
spectrometry
Explore network properties of
LoF tolerant genes
Gene annotations, interac
multiple network databas
Explore molecular basis of
genotype–phenotype
relationships
Mutation databases, PPI 
Explore the relationship between
network state and cellular
outcome
TP53 signaling network, 
specific cellular outcome
Evaluate how a network motif
contributes to cell fate decisions
Cell cycle pathway, yeas
to mating pheromones
Explore how drugs rewire
biological networks
Time series gene express
cellular response, growth
signaling and DNA dama
response pathways
Explore how SNPs effect gene
expression in different tissues
Microarray based SNP a
expression measurement
Organize genetic interaction as a
hierarchical network
Genetic interaction scree
Organize interaction edges in a
hierarchical ontology of terms
Physical and genetic inte
mRNA co-expression
www.sciencedirect.com mutations implicated by association studies onto holistic
network models can implicate underlying biological pro-
cesses (Table 2). In a recent GWAS of coronary artery
disease (CAD), Deloukas et al. identified subnetworksl mechanisms underlying genetic disorders. Methods are grouped
 genotype to phenotype, while Analytic Methods seek to uncover a
disorder (LoF = loss of function, PPI = protein–protein interaction,
s).
Strategy References
ein GeneHits: method based on graph kernel
diffusion
[16]
n/mass MiST: uses information about protein
abundance, reproducibility and specificity
across replicate experiments
[17]
tions from
es
Use custom Multinet to investigate
statistical correlation between genes and
network properties, fit a linear model to
separate essential and LoF tolerant genes
using network properties
[58]
databases Build a PPI network with structurally
resolved protein interaction interfaces for
analysis of mutations in inherited diseases
[25,26]
condition
 data
Build a Boolean model of simplified TP53
signaling, map model dynamics to cellular
outcomes, use the model to simulate how
removing genes affects cellular outcome
[28]
t response Generate hypotheses based on network
structure, test experimentally and build
differential equation models
[29]
ion,
 factor
ge
Identify candidate genes from pathways or
DE after drug exposure, select a subset of
genes based on prior knowledge or
pathway structure, use time series data for
genes model signaling to cellular outcome
[31]
nd
s
Combine eQTL analysis with a sampling
approach to detect tissue specific SNP
effects on expression
[64]
ns in yeast A minimum description length criteria is
minimized using greedy and local search
methods from an initial clustering.
[67]
ractions, Combine probabilistic clustering with an
ontology alignment method to produce
robust hierarchical structure directly from
experimental measurements and networks.
[41,90]
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Table 2 (Continued )
Type Goal Data Strategy References
Analytic Identify biological pathways
underlying
hemimegalenchephaly
De novo somatic mutations,
pathway gene sets
Map onto canonical pathways [8]
Identify disease genes from de
novo CNVs in autism cases
De novo CNVs, protein architecture,
function, and expression, pathways
Identify genes across CNVs implicated in
similar phenotypes
[19]
Identify biological pathways
underlying CAD
CAD GWAS loci, commercial
network database
Identify subnetworks from GWAS
implicated genes, annotate subnetworks,
identify overlap with canonical pathways
[15]
Identify genes underlying type 1
diabetes
GWAS loci, protein interaction
network, gene expression
Identify subnetworks from GWAS
implicated genes, map DE onto
subnetworks and test for statistical
enrichment of DE genes
[56]
Identify genes underlying autism De novo somatic mutations, protein
interaction network
Identify connected subnetworks based on
de novo mutated genes, functionally
annotate subnetworks
[57]
Identify genes that regulate
plasma insulin levels
Genotypes, clinical traits,
transcriptional, hybrid network
Identify subnetworks from eQTLs in
different tissues, prioritize genes that
participate in inter-subnetwork edges
[59]
Identify cancer related genes
and pathways
Gene expression data and SNP data A set-cover based approach is used to
identify subnetworks which explain an
eQTL relationship between causal genes
and potential targets
[81]enriched for genes implicated by variable expression with
or physical proximity to SNPs in a larger protein–protein
interaction (PPI) network [15]. Subsequent gene set
analysis to determine functional enrichment of the subnet-
works, and analysis of subnetwork overlap with canonical
pathways implicated crosstalk between lipid metabolism
and inflammatory pathways as underlying the pathogenesis
of CAD.
If the disease is better understood, focused models may
enable development of specific biological hypotheses
about the mechanisms by which alterations cause disease.
For example, Chu et al. constructed a network of protein
interactions involved in angiogenesis, which they dub
‘the angiome’, in order to study diseases related to irre-
gular blood vessel formation [16]. In another example, a
network of human-HIV protein complexes constructed
by affinity tagging and purification mass spectrometry has
provided a near-comprehensive view of how HIV evades
host cell defenses [17]. While focused approaches
represent only a partial view of the cell, the resulting
networks provide an intelligent framework for constrain-
ing hypothesis testing to proteins most relevant to a
disease. On the other hand, focused screens may miss
systems level trends, for example cross-talk between
biological processes, that can play a role in disease [18].
Network edges can also represent abstract relationships
derived from biological knowledge. Gilman et al. built a
network where all pairs of proteins are connected by a
weighted edge representing the a priori expectation that
the proteins participate in the same phenotype. Edge
weights were based on evidence sources such as tissue-
specific expression, pathway membership, common func-
tional annotations and similar domain composition [19].Current Opinion in Genetics & Development 2013, 23:611–621 They then searched over this network to identify the
most functionally similar genes affected by de novo copy
number variants (CNVs) in autism cases.
Mutations as network perturbations
The majority of known disease mutations annotated in
the Human Gene Mutation Database (HGMD) cause
changes to the amino acid sequence of proteins [20].
These changes can have a spectrum of consequences
ranging from completely abrogating protein activity to
having no effect at all, and a variety of computational
strategies have been developed to predict the functional
consequences of mutation at the protein level [21–23].
Changes to a protein’s activity are indirectly linked to
altered cellular behaviors by the network of molecular
interactions in which it participates. Thus it has been
proposed that to understand genotype–phenotype
relationships it will be necessary to quantify the effects
of mutations on molecular networks [24].
To investigate how interaction networks mediate pheno-
typic effects of mutations, Zhong et al. experimentally
profiled protein interactions for twenty-nine alleles
associated with five genetic disorders [25]. This profiling
suggested that mutations could have three distinct effects
for the PPI network: they could eliminate all interactions,
remove a subset of interactions, or have no effect on
interactions. To more systematically study how mutations
affect physical interaction networks, Wang et al. con-
structed a high quality PPI network with structurally
resolved interaction interfaces [26]. Using this network,
they analyzed disease-associated mutations from OMIM
[27] and HGMD and demonstrated enrichment for in-
frame mutations such as or in-frame insertions and
deletions at interaction interfaces. They also found thatwww.sciencedirect.com
Genotype to phenotype via network analysis Carter, Hofree and Ideker 615mutations occurring at distinct interaction interfaces in
the same protein could explain many cases where a single
gene is involved in multiple disorders (i.e. pleiotropy) or
in disorders with multiple distinct modes of inheritance
[25,26].
Models of how PPIs are rewired by mutations, some-
times referred to as ‘network perturbation models’,
may present a useful strategy for functionally prior-
itizing candidate disease mutations and developing
hypotheses about biological processes underlying
pathogenesis  [4,25]. These models can also be used
to analyze the combined effects of multiple mutation
and expression changes. For example, TP53 signaling
is associated with cell cycle arrest and apoptosis in
response to cell damage. Choi et al. used a simplified
model of the TP53 signaling network to map combi-
natorial network perturbations to cellular outcome
[28]. They then used this model to explore how
fixing the activation of specific molecules constrained
the cellular behaviors available and what parts of the
network could be targeted with therapeutics to force
the apoptotic state. Relatedly, Doncic and Skotheim
recently  found that a simple three-gene motif
embedded within a more complex network structure
was sufficient to explain yeast cellular state decisions
in response to mating pheromone, suggesting that it
may not be necessary to model the full complexity of
biological networks to capture molecular determinants
of cellular behaviors [29].
In addition to the effects on individual edges in the
network, downstream processes in the cell may be
rewired to maintain homeostasis in the face of pertur-
bations [30]. Intriguingly, Lee et al. showed that delib-
erate perturbation of networks to achieve specific
rewiring could serve as a therapeutic strategy in cancer
[31]. Triple negative breast cancer cells exposed to an
EGFR inhibitor before chemotherapy showed increased
sensitivity to genotoxic therapy. The timing of exposure
to EGFR inhibitor greatly influenced sensitivity to sub-
sequent chemotherapy suggesting that temporal
dynamics of network rewiring are a determinant of cel-
lular response to environment.
In studies of inherited disease, causal mutations are often
buried in a list of candidate variants uncovered by
sequencing of risk loci or disease exomes [32], and in
cancers, the majority of detected somatic mutations are
thought to be neutral ‘passenger’ events [33,34]. It has
also been suggested that most post-translational modifi-
cations may not affect protein activity [35]. Information
about protein sequence and structure provides important
clues for discriminating effects of distinct alterations to
proteins [21–23]. Thus integrated approaches combining
protein sequence and structural information with net-
works may provide a powerful framework for identifyingwww.sciencedirect.com disease mutations and reasoning about their molecular
mechanisms.
The biophysical mechanisms by which mutations alter
protein interactions are diverse and are usually not cap-
tured in the abstractions provided by simple interaction
networks [36,37]. Mutations altering protein confor-
mation or binding affinity can contribute to disease phe-
notype without removing network edges [38–40].
Furthermore, highly connected proteins in the network
are unlikely to interact with all partners simultaneously,
as interaction interfaces often overlap [41,42]. Network
representations that capture mutual exclusivity of bind-
ing may be helpful for predicting the functional con-
sequences of mutations [37,42,43].
Structurally resolved interaction networks are becoming
available for several species through databases such as
Interactome3D and INstruct [44,45]. Studying candidate
disease mutations in the context of these networks may
provide important clues as to how mutations affect bio-
logical processes. Because of the limited availability of co-
crystallization protein structures [46] strategies have been
developed to predict structure at protein interfaces using
homology models [26]. Nonetheless, this type of analysis
will only be possible for a subset of candidate disease
mutations.
Joint study of co-evolution of amino-acid residues at
protein interfaces and network structure may provide
insights into which residues are essential for maintain-
ing interactions [40,47,48]. Fridman et al. found that
affinity-altering mutations in proliferating cell nuclear
antigen (PCNA) could have more severe consequences
for DNA replication and repair than mutations com-
pletely abolishing interactions [40]. Their findings
suggest that even within interfaces, mutations are
likely to have distinct phenotypic consequences. Thus
it may be important to include manipulation of specific
interactions as part of mutagenesis studies when
experimentally evaluating candidate disease genes.
Emerging genome engineering strategies provide
exciting opportunities for experimentally characteriz-
ing domain specific effects of mutations on network
activities [49].
Network properties of human disease genes
The non-random organization of biological networks
suggests that their topology may encode information
about how molecular interactions contribute to biological
phenotypes [50]. Molecular interaction networks within
the cell tend to be modular; that is, proteins related to the
same biological activities often form connected modules
within networks [5–7,50,51]. Goh et al. showed that this
phenomenon extends to disease genes as well; genes
implicated in the same diseases often cluster within
PPI networks [52,53].Current Opinion in Genetics & Development 2013, 23:611–621
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interactome networks supports a ‘guilt-by-association’
(GBA) strategy for identifying novel disease-associated
genes [5,54]. GBA has been used to intelligently reduce
the list of candidate disease genes in association studies
[54,55]. Bergholdt et al. combined PPI network overlap
with genes located at GWAS risk loci and subnetwork-
based enrichment for differential expression to identify
new candidate type I diabetes disease genes [56]. Identi-
fication of network modules enriched for mutation or
variable expression under disease conditions can point to
specific biological processes disrupted in disease. For
example, analysis of the network distribution of de novo
mutations in sporadic cases with autism spectrum disorders
implicated a highly interconnected subnetwork of proteins
involved in b-catenin/chromatin remodeling [57].
Goh et al. also investigated differences in network connec-
tivity of three classes of genes: essential, inherited and
somatic disease genes [52,53]. They reported that essential
genes were more likely to have a large number of inter-
action partners and therefore be central in the network,
while inherited disease genes generally had fewer inter-
action partners and were more peripheral. By contrast,
somatic disease genes often looked more like essential
genes. Khurana et al. further explored gene essentiality and
selection in the context of different types of biological
network (PPI, metabolic, post-translational modification,
regulatory, etc.) as well as in a pooled network and found
that highly connected genes are more likely to show strong
signatures of selection [58]. Using topological and selection
properties of genes, they built a logistic regression model
capable of distinguishing essential genes from genes tol-
erant to loss-of-function events, suggesting that these
properties could be useful for selecting candidate genes
for sequencing and follow-up studies. Tu et al. used topo-
logical location at the interface between subnetworks with
differential expression (DE) mediated by plasma-insulin
associated genetic loci to implicate an Alzheimer’s related
gene, App, in type 2 diabetes [59].
These applications demonstrate how characteristics of
biological networks such as topology and modularity can
be used to prioritize candidate disease genes implicated
by association studies. Inference based on network archi-
tecture may be particularly sensitive to the previously
noted ascertainment biases that can affect network models;
highly studied genes are more likely to have a large
number of edges in the network than less frequently
studied genes [4,5,18]. This is less of an issue for networks
derived from systematic experimental screens [4,7,60],
although technology-specific biases are suspected to exist
[61].
Lessons from cross-species network analysis
Mounting evidence from both the study of model organ-
isms [62,63] and GWAS [64,65,4] suggests that muchCurrent Opinion in Genetics & Development 2013, 23:611–621 of the ‘missing heritability’ of genetic disease may result
from genetic interactions (GIs). GI maps have been
widely used to study epistatic phenomena in model
organisms [29,51,66,67] and have more recently been
applied to mammalian species and human cell lines.
The most comprehensive GI networks to date have
been generated from systematic screens in model organ-
isms. For this reason, it is of interest to determine
whether studies of orthologous proteins in model organ-
isms could inform missing interactions in human net-
works. In a recent attempt to experimentally address
this question on a systems level, two evolutionarily
diverged yeast species were compared: the budding
yeast Saccharomyces cerevisiae and the fission yeast Sac-
charomyces pombe, which are separated by an estimated
400–800 million years of evolution (an evolutionary
distance greater than the divergence between humans
and fish). Comparison of systematic pairwise genetic
interaction screens conducted in both species [18,68,69]
showed a hierarchical conservation of network modules,
with highest conservation observed for interactions
within protein complexes (68–70%), lower conservation
of interactions within biological processes (38–58%) and
lowest conservation of interactions between distinct
biological processes (15–19%) [18]. In some cases, there
was functional ‘repurposing’ of complexes between
species [69].
Interestingly, although globally only a small fraction of
the specific interactions between biological processes
were conserved, the total number of interactions was
similar, suggesting that coordination of biological pro-
cesses may be a design principle in eukaryotic systems
[18]. Because of the aforementioned divergence between
these yeast species, Ryan et al. suggest that these trends
will most likely pertain to other eukaryotic species as
well. These studies provide compelling evidence that
cross-species networks can aid our understanding of
human disease proteins and the biological processes in
which they participate.
A uniquely informative perspective is afforded by exam-
ining ‘difference networks’, which are emerging as an
exciting strategy to examine the broader effects of per-
turbations on biological processes in the cell [30]. Differ-
ence networks can be derived from systematic mapping of
interactions in cells under different conditions. In these
networks, edges represent the interactions that differ
between the tested conditions and can capture more
dynamic effects of particular (e.g. drug) or environmental
(e.g. heat) perturbations on the network [66,70].
Regulatory networks and non-coding DNA
Most GWAS-implicated risk variants occur outside of
protein coding genes [71–73]. Recently it has been
suggested that the majority of the genome is involvedwww.sciencedirect.com
Genotype to phenotype via network analysis Carter, Hofree and Ideker 617in biochemical and regulatory activities, not just the 1.5%
encoding proteins [74]. Non-coding genetic alterations,
even those affecting non-coding RNA (ncRNA)
sequence, are suspected to mediate phenotypic effects
primarily by altering the abundance of proteins in the cell
and thus perturbing PPI networks through stoichiometric
effects [75–77]. Indeed, many variants detected by
GWAS are located at DNA regulatory elements [78].
An early investigation of the tissue-specific effects of
genetic variants on gene expression uncovered surpris-
ingly complex relationships, suggesting that network
models may be essential for dissecting phenotypic con-
sequences of non-coding variation [64].
An analysis conducted as part of the Encyclopedia of
DNA Elements (ENCODE) project [79] compared the
genome-wide binding patterns of 119 distinct transcrip-
tion and DNA binding factors (TFs) across five different
cell lines [80]. These data were used to construct a
hierarchical representation of transcription factor regula-
tion onto which protein and non-coding RNA interaction
data as well as post-translational modifications were inte-
grated. The combined network suggested the existence
of three tiers of transcriptional regulation with distinct
properties and architectures. Kim et al. used an interaction
network of similar composition to implicate genes and
network paths capable of mediating disease-related
expression changes downstream of copy number variants
[81].
Increasing evidence points to an important role for
ncRNAs in complex disorders. On the level of mutations,Figure 2
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www.sciencedirect.com microRNAs (miRNAs) have been shown to play a
mechanistic role in the effects of often ignored synon-
ymous mutations [14]. A recent work has shown that a
network of microRNAs may play a key role in the epi-
thelial to mesenchymal transformation of ovarian cancers
[82]. The importance of other ncRNA species have also
been highlighted, such as the role of anti-sense RNAs on
PTEN regulation [83], broad epigenetic effects of
HOTAIR a long intergenic ncRNA (lincRNA) in breast
cancer [12], and the role of PCAT-1, another lincRNA, on
the progression of prostate cancer [13].
Future challenges: context, dynamics and
hierarchies
Biological network models still fall short of capturing
many important aspects of biological systems. Cells exhi-
bit dynamic responses to environmental stimuli [84] and
cells of different tissue types are characterized by distinct
gene expression patterns [10,64]. These properties are
key determinants of phenotype but are not captured by
the standard static network models that are prevalent in
the field.
Attempts to estimate the completeness and accuracy of
existing protein interaction data suggest that 92% or more
of binary human PPIs remain to be uncovered [3,85].
These estimates do not account for the possibility that
distinct protein isoforms participate in different inter-
actions. In addition, new molecular species are still being
discovered and have not yet been incorporated into net-
work models [7]. Constructing network models that accu-
rately capture the molecular composition and interactions(c)
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etworks contribute to biological function. The subnetwork comprising
ng different network layouts: (a) hierarchical, (b) force-directed and (c) a
archical representation, distal nodes are included in proximal nodes (e.g.
 in red and cyan). Node size corresponds to the number of genes
 annotated biological activities. Branches and nodes corresponding to
 in panels (b) and (c) match the complexes highlighted in panel
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618 Genetics of system biologyin specific cell types and under distinct conditions will be
essential for effectively modeling genotype–phenotype
relationships.
New experimental techniques are rapidly emerging that
will enable systematic screens of molecular interactions in
mammalian cells. Mass spectrometry (MS)-based tech-
niques promise to enable systematic cell type-specific
screens of the proteome and protein post-translational
modifications [61]. Proteomics may also aid in discovery
of as yet undiscovered protein coding genes [86]. Until
now, the majority of GI screens have been performed in
model organisms, especially yeast, by exhaustively
knocking out pairs of genes and measuring the effects
on colony size. Novel approaches using RNAi technol-
ogies are now enabling systematic mapping of GIs in
mammalian cells [87–89].
New strategies for network construction and visualization
will also aid the search for disease causing genes and
mutations. Reformulating interactomes as hierarchies can
provide representations of biological information that are
easier to interpret than the typical ‘hairball’ that results
when thousands of interactions are simultaneously dis-
played [41,90] (Figure 2). Mapping molecular measure-
ment data onto such hierarchies will provide novel
biological hypotheses about the pathogenesis of complex
inherited disease. Furthermore, the hierarchical structure
can highlight inconsistent edges likely to be false posi-
tives or of lesser importance, and suggest new relation-
ships among distinct biological complexes and processes.
Aside from a few pioneering efforts, the space of hier-
archical network modeling remains largely unexplored.
Conclusions
Biological networks are increasingly being applied to
study the mechanisms by which genetic alterations cause
phenotypic changes at the cellular level. Network organ-
ization and structure can help explain many disease
phenomena such as locus heterogeneity, variable pene-
trance, pleiotropy, inheritance models and comorbidity.
We believe these efforts are in their infancy. Limited
knowledge of the dynamic and context-specific interplay
of molecules within cell and our incomplete understand-
ing of the makeup of the human genome has prevented
effective modeling of the heritable contributions to
human disease. Advances in experimental measurement
technologies will soon enable large-scale screens to fill in
much of our missing knowledge.
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